Overview

A Study of ASP8302 in Participants With Underactive Bladder

Status:
Completed
Trial end date:
2020-04-28
Target enrollment:
Participant gender:
Summary
The study objectives of this study are to evaluate the efficacy of ASP8302 compared with placebo in participants with underactive bladder (UAB), to investigate the safety and tolerability of ASP8302 compared with placebo in participants with UAB, to investigate the pharmacokinetics of ASP8302 in participants with UAB and to support the development of the UAB - Patient Reported Outcome (PRO).
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Europe B.V.